• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

HCA Red Flag: Demant upgrades outlook more than analysts expected (AI)

DEMANTAnalyst Comment11.08.2026 klo 18.56
HC Andersen Capital

Summary

  • Demant raised its 2026 operating profit midpoint to DKK 4,600 million, surpassing the DKK 4,539 million expected by analysts, with revenue growing 18% before currency effects.
  • The operating margin slightly improved to 16.5% from 16.4% last year, despite the revenue growth, requiring adjustments for currency and a British retail acquisition.
  • One-off costs for restructuring and integrating KIND increased to DKK 400 million, with an additional DKK 100 million expected in 2027, attributed to faster execution and earlier factory closure.
  • The gross margin improved to 77.1%, driven by higher prices per hearing aid, and Demant is rolling out Oticon Reveal, a new AI-powered hearing aid platform, starting this month.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Automatic translation: Originally published in undefined 11/08/2026, 15:56 GMT. Give feedback here.

Red Flag · First reading of the financial report · AI-generated content
Demant (DEMANT) · H1 2026 · August 11
Shares +20% in 3 months, 2% from 12-month peak
Overall assessment
Positive reading
 
 
Positive reading Balanced Negative reading
Shares are expected to open higher: Demant raised its 2026 operating profit midpoint to DKK 4,600 million, above the DKK 4,539 million analysts expected. The catch: revenue grew 18% before currency effects, and the operating margin still only reached 16.5% vs. 16.4% last year.
Red flags in the financial report
The margin barely budged despite growth
16.5% · H1 2025: 16.4%
Revenue grew 18% before currency effects, but the operating margin landed at 16.5% vs. 16.4% the previous year. Demant must adjust for currency and a British retail acquisition to show a 0.6 percentage point improvement.
The second half of the year must carry the heavy load
H2 implicitly approx. DKK 2,466 million · H1 DKK 2,134 million
The new midpoint requires an operating profit of around DKK 2,466 million after June, 17% more than the same half last year. This is based on DKK 200 million in savings that are still pending, and on Oticon Reveal, which has not yet reached a single customer.
One-off costs are increasing
Now: DKK 400 million · Previously: DKK 325 million
One-off costs for restructuring and integrating KIND, the German chain acquired in December, increased to DKK 400 million from DKK 325 million, with an additional DKK 100 million to follow in 2027. Demant attributes this to faster execution, including an earlier closure of KIND's factory in Kölleda.
Green flags in the financial report
The upward revision exceeds analysts' figures
New midpoint DKK 4,600 million · Expected DKK 4,539 million
Demant raised the operating profit range before one-off costs in 2026 to DKK 4,400 to DKK 4,800 million, a midpoint above the DKK 4,539 million analysts had already factored into their models. The underlying savings program now delivers DKK 300 million this year, up from DKK 250 million.
The gross margin broke out of its own range
77.1% · H1 2025: 76.0%
The gross margin reached 77.1%, exceeding the 76% to 77% range Demant has reported for years, and 1.1 percentage points better than the previous year. Higher prices per hearing aid drove this increase, reversing the 2% price decline that impacted 2025.
The missing platform has been named
New: Oticon Reveal, rollout from August
This month, Demant is beginning to roll out Oticon Reveal, a premium-class hearing aid built on a new sound system powered by artificial intelligence. At the February conference call, analysts asked if the two-year launch cadence had been broken; the financial report answers that question.
Disclaimer: This is an HCA AI-generated research commentary based solely on the company's published financial report. The commentary does not constitute investment advice and should not be the sole basis for investment decisions. Investing in shares involves a risk of loss. Seek professional advice. /HC Andersen Capital, 17.55, 11.08.2026
Login required

This content is only available for logged in users

Create account

Demant operates in the medical technology sector. The company specializes in the development of hearing aids and hearing loops. The company operates on a global level where the products are sold under various brands. The products are available through the company's distributors and sales channels. In addition to its main business, the company conducts research in diagnostics for measuring hearing quality. The company was originally founded in 1904 and has its headquarters in Smörum.

Read more on company page